Catalyst Pharmaceuticals (CPRX)
(Delayed Data from NSDQ)
$12.18 USD
-0.53 (-4.17%)
Updated Sep 20, 2023 04:00 PM ET
After-Market: $12.19 +0.01 (0.08%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth F Momentum B VGM
Catalyst Pharmaceutical (CPRX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$23.10 | $27.00 | $15.50 | 81.75% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for Catalyst Pharmaceutical comes to $23.10. The forecasts range from a low of $15.50 to a high of $27.00. The average price target represents an increase of 81.75% from the last closing price of $12.71.
Analyst Price Targets (5 )
Broker Rating
Catalyst Pharmaceutical currently has an average brokerage recommendation (ABR) of 1.40 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 1.40 a month ago based on five recommendations.
Of the five recommendations deriving the current ABR, four are Strong Buy, representing 80% of all recommendations. A month ago, Strong Buy represented 80%.
Broker Rating Breakdown

Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.40 | 1.40 | 1.40 | 1.40 | 1.40 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/22/2023 | Cantor Fitzgerald & Co | Charles C Duncan | Strong Buy | Strong Buy |
8/11/2023 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
6/20/2023 | Truist Securities | Joon Lee | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.40 |
ABR (Last week) | 1.40 |
# of Recs in ABR | 5 |
Average Target Price | $23.10 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 105 of 252 |
Current Quarter EPS Est: | -0.03 |